Skip to main content

Day: May 28, 2020

Cartier Cuts 16.5 g/t Au over 4.5 m at Chimo Mine 500 m below the New Zones 5B4-5M4-5NE

Highlights:Mineralised intersection of 32.0 g/t Au over 2.0 m included within 16.5 g/t Au over 4.5 m, also included within 7.1 g/t Au over 12.1 m, located 500 m below the new Zones 5B4-5M4-5NE in the East Sector of the Chimo Mine Property; The results of this press release, factored with those of the May 21st2020, April 7th2020 and February 18th2020 press releases, increase the potential for expansion of the resource estimate to date for the new Zones 5B4-5M4-5NE (FIGURE); The Chimo Mine Property hosts three gold-bearing corridors (North, Central and South) that to date host the following mineral resources: — 4,017,600 tonnes at an average grade of 4.53 g/t Au for a total of 585,190 ounces gold in the Indicated Category;— 4,877,900 tonnes at an average grade of 3.82 g/t Au for a total of 597,800 ounces gold in the Inferred...

Continue reading

Cartier recoupe 16,5 g/t Au sur 4,5 m à Mine Chimo 500 m sous les nouvelles Zones 5B4-5M4-5NE

Faits saillants :Intersection minéralisée de 32,0 g/t Au sur 2,0 m incluse dans 16,5 g/t Au sur 4,5 m, elle-même incluse dans 7,1 g/t Au sur 12,1 m, à une distance de 500 m sous les nouvelles Zones 5B4-5M4-5NE du Secteur Est ;Les résultats de ce communiqué, associés à ceux du 21 mai 2020, 7 avril 2020 et du 18 février 2020, accroissent considérablement le potentiel d’expansion des ressources estimées à ce jour pour les nouvelles Zones 5B4-5M4-5NE (FIGURE) ;La propriété Mine Chimo contient trois Couloirs Aurifères (Nord, Central et Sud) et possède à ce jour les ressources minérales suivantes :— 4 017 600 tonnes à une teneur moyenne de 4,53 g/t Au pour un total de 585 190 onces d’or dans la catégorie de ressources indiquées ;— 4 877 900 tonnes à une teneur moyenne de 3,82 g/t Au pour un total de 597 800 onces d’or dans la catégorie...

Continue reading

WPD Pharmaceuticals Licensor Granted Another Key Patent for the Development of WPD101 Drug Candidate

VANCOUVER, British Columbia, May 28, 2020 (GLOBE NEWSWIRE) — WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”), a clinical stage pharmaceutical company, is pleased to announce that on May 21, 2020 Wake Forest University received a patent from the United States Patent and Trademark Office (“USPTO”) for a patent titled “EphA3 and Multi-Valent Targeting of Tumors” (under application number 15/958,608). The patent is exclusively licensed to WPD, and the patent relates to the WPD101 drug candidate, used in the therapy of glioblastoma multiform (“GBM”). Mariusz Olejniczak, CEO of WPD commented, “We are very excited to receive another patent included in the license agreement with Wake Forest University. This patent covers EPHA3 and multi-valent targeting of tumors and provides an additional layer of protection for...

Continue reading

Osino Resources Drills Additional Wide Gold Intercepts and Further Increases Strike of Mineralization at Twin Hills Central Discovery, Namibia

Assays have been received for the first 4 holes of the 2020 drill program at Twin Hills CentralHighlights from the latest results include:   ∙  150m @ 0.98g/t (OKD031: 23 – 173m), incl. 61m @ 1.51g/t   ∙  77m @ 0.72g/t (OKD032: 98 – 175m), incl. 15m @ 1.33g/t and 12m @ 1.36g/t   ∙  10m @ 1.23g/t (OKD030: 25 – 35m)Gold mineralized strike extended to 1300m, open to the east, west and down dipA total of 2,000m of the 20,000m drill program planned for 2020 has been completed so far with two diamond rigs active at Twin Hills Central, and a third rig active at Twin Hills WestThe objective of the program is expansion drilling and resource definition at Twin Hills Central as well as additional satellite discovery along strike, aiming to complete a NI 43-101 compliant maiden resource report for Twin Hills Central in the first half of 2021VANCOUVER,...

Continue reading

Translate Bio to Present at Jefferies Virtual Healthcare Conference

LEXINGTON, Mass., May 28, 2020 (GLOBE NEWSWIRE) — Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that Ronald Renaud, chief executive officer, will participate in a fireside chat at the Jefferies Virtual  Healthcare Conference on Wednesday, June 3, 2020, at 1:00 p.m. ET.A live webcast of the session will be accessible through the “Events and Presentations” page of the Company’s website at investors.translate.bio. A replay of the webcast will be archived on the Translate Bio’s website for 30 days following the presentation.About Translate BioTranslate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative...

Continue reading

Abercrombie & Fitch Co. Reports First Quarter Results

Company continues to reopen stores globally on a rolling basis with roughly half of the fleet currently openQ1 results reflect strong cash flow management and month-over-month acceleration in digital sales growth, partially offsetting sales decline from temporary store closuresNet loss per diluted share of $3.90 reflects adverse tax impacts of $1.45 related to valuation allowances on deferred tax assets and other tax charges and $0.62 related to asset impairment chargesNEW ALBANY, Ohio, May 28, 2020 (GLOBE NEWSWIRE) — Abercrombie & Fitch Co. (NYSE: ANF) today announced results for the first quarter ended May 2, 2020. These compare to results for the first quarter ended May 4, 2019. Descriptions of the use of non-GAAP financial measures and reconciliations of GAAP and non-GAAP financial measures accompany this release.Details...

Continue reading

MacroGenics Provides Update on FDA Review of Margetuximab for HER2-Positive Metastatic Breast Cancer

– Advisory committee meeting not required; PDUFA goal date unchangedRockville, MD, May 28, 2020 (GLOBE NEWSWIRE) —MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that during the recent mid-cycle communication with the U.S. Food and Drug Administration (FDA), the FDA notified the Company that it is no longer planning to hold an Oncologic Drugs Advisory Committee (ODAC) meeting to discuss the Biologics License Application (BLA) for margetuximab. The FDA also stated it continues to anticipate meeting the Prescription Drug User Fee Act (PDUFA) goal date for the application review, which is December 18, 2020.“Since submitting the BLA for margetuximab, we have worked...

Continue reading

DraftKings Sportsbook Expands Partnership with Sportradar to Launch Mobile Live Streaming

BOSTON, May 28, 2020 (GLOBE NEWSWIRE) — Today, DraftKings Sportsbook has announced it will offer live-streamed sports games within its award-winning mobile app. In collaboration with Sportradar, the global provider of sports data and content, DraftKings Sportsbook will provide customers with a seamless entertainment experience in one convenient location.Pursuant to state regulations, DraftKings Sportsbook customers who are logged in to their active accounts and have a wallet balance above $0.00 will have the ability to live stream games directly within the mobile app. At launch, DraftKings Sportsbook geolocated customers will be able to live stream a number of sports, including the Korea Baseball Organization and Bundesliga Soccer (Division 1) across all jurisdictions except Iowa. With over 100 different leagues in total on the...

Continue reading

Deveron Reports Q1 Revenue Growth of 181%

TORONTO, May 28, 2020 (GLOBE NEWSWIRE) — Deveron UAS Corp. (CSE: DVR) (“Deveron” or the “Company”), a leading agriculture digital services and insights provider in North America, is pleased to announce revenue growth of 181% year over year to $283,420 in Q1 2020.  For the fourth quarter in a row, Deveron achieved sales growth of over 100%.First Quarter 2020 Financial and Operational HighlightsThe Company’s financial performance improved over the previous year’s quarter, driven by the continued customer uptake of Deveron’s soil sampling service.  For the three-month financial results ended March 31, 2020 (and comparable period ended March 31, 2019):Revenue grew 181% year over year to $283,420 in Q1 2020, from $100,564 in Q1 2019. Gross profit grew 160% year over year to $180,212 in Q1 2020, from $69,833 in Q1 2019.“Our first quarter...

Continue reading

Biogen and MIT Launch New Virtual Learning Lab for High School Students Historically Underrepresented in Science

The online learning program combines lab simulations and mentoring experiences focused on biotechnology and neurological diseases, such as Parkinson’s disease, Alzheimer’s disease and multiple sclerosisFour hundred students from Massachusetts and North Carolina are enrolling in this no-fee program that also provides students with computers and other technology resourcesThe initiative builds upon Biogen’s Community Lab, which has enrolled more than 55,000 students to date, and the Lemelson-MIT Program in inspiring the next generation of creative and inventive problem-solversCAMBRIDGE, Mass., May 28, 2020 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) is bringing its well-recognized Community Lab science learning program together with the Lemelson-MIT Program (LMIT) at the Massachusetts Institute of Technology to launch the new online...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.